MedTrace Logo

Clinical and Device Functional Assessment of Real World ICD Patients

NCT02341768 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2056

Last updated 2020-08-17

No results posted yet for this study

Summary

The primary requirement of the implantable cardioverter defibrillator (ICD) is to preserve life by terminating life-threatening arrhythmias (VT/VF). The treatment options vary in terms of techniques and medical devices, based on the patient's condition.

It is extremely important in the clinical practice to identify which patients' subgroup benefits the most from the ICD therapy, which comorbidity has a major impact on the patients' prognosis, or which pre-intra-post procedural behaviors provoke less complications, and affect the patient's outcome (including prolonged or unwanted hospitalizations).

Conditions

  • Arrythmia
  • Implantable Cardioverter Defibrillator

Interventions

DEVICE

ICD

ICD single, dual or triple chamber, upgrade, replacement or primo implant

Sponsors & Collaborators

  • MicroPort CRM

    lead INDUSTRY

Principal Investigators

  • Javier Moreno, Dr · Hospital Ramón y Cajal Ctra. de Colmenar Viejo km 9.100, 28034 Madrid, Spain

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2019-11-26
Completion
2019-11-26

Countries

  • Austria
  • Canada
  • Czechia
  • France
  • Germany
  • Italy
  • Netherlands
  • Portugal
  • Slovakia
  • Spain
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02341768 on ClinicalTrials.gov